» Articles » PMID: 15019282

Broad-spectrum Immunity Against Superantigens is Elicited in Mice Protected from Lethal Shock by a Superantigen Antagonist Peptide

Overview
Journal Immunol Lett
Date 2004 Mar 17
PMID 15019282
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Bypassing the restricted presentation of conventional antigens, superantigens trigger an excessive cellular immune response leading to toxic shock. Antagonist peptides that inhibit the induction of human Th1 cytokine gene expression by a variety of bacterial superantigens protect mice from lethal toxic shock. We show that the surviving mice rapidly develop a broad-spectrum, protective immunity against further lethal toxin challenges with the same superantigen and even with superantigen toxins that they have not encountered before. By blocking the induction of a cellular immune response leading to toxic shock, the antagonist peptide allows the superantigen to induce a vigorous humoral immune response directed against itself, resulting in anti-toxin IgM and IgG that are broadly protective. Adoptive transfer of these antibodies to naïve mice rendered them resistant to lethal superantigen challenge. The appearance of these antibodies does not require immunization with an adjuvant and is not elicited by the antagonist peptide. Our results show that superantigens are potent immunogens when given the opportunity to induce a B cell response, in conditions where a deleterious Th1 response is prevented by the superantigen antagonist peptide.

Citing Articles

Staphylococcal and Streptococcal Superantigens Trigger B7/CD28 Costimulatory Receptor Engagement to Hyperinduce Inflammatory Cytokines.

Popugailo A, Rotfogel Z, Supper E, Hillman D, Kaempfer R Front Immunol. 2019; 10:942.

PMID: 31114583 PMC: 6503043. DOI: 10.3389/fimmu.2019.00942.


Drugs in Development for Acute Kidney Injury.

Hulse M, Rosner M Drugs. 2019; 79(8):811-821.

PMID: 31004331 DOI: 10.1007/s40265-019-01119-8.


Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor.

Chen G, Karauzum H, Long H, Carranza D, Holtsberg F, Howell K J Mol Biol. 2019; 431(21):4354-4367.

PMID: 30928493 PMC: 6764902. DOI: 10.1016/j.jmb.2019.03.017.


CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.

Ramachandran G, Kaempfer R, Chung C, Shirvan A, Chahin A, Palardy J J Infect Dis. 2014; 211(6):995-1003.

PMID: 25305323 PMC: 4416127. DOI: 10.1093/infdis/jiu556.


CD28: direct and critical receptor for superantigen toxins.

Kaempfer R, Arad G, Levy R, Hillman D, Nasie I, Rotfogel Z Toxins (Basel). 2013; 5(9):1531-42.

PMID: 24022021 PMC: 3798871. DOI: 10.3390/toxins5091531.